<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01762501</url>
  </required_header>
  <id_info>
    <org_study_id>ACS1</org_study_id>
    <nct_id>NCT01762501</nct_id>
  </id_info>
  <brief_title>Azilsartan Circadian and Sleep Pressure</brief_title>
  <official_title>Azilsartan Circadian and Sleep Pressure - the 1st Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sogo Rinsho Médéfi Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sogo Rinsho Médéfi Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of Azilsartan 20 mg versus Amlodipine 5 mg oral administration once
      per day for 8 weeks in patients with grade I or grade II essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment

      &lt;Run-in period&gt; Use of any antihypertensives, including azilsartan and amlodipine, is
      prohibited during the run-in period.

      &lt;Treatment period&gt; Subjects who are considered eligible for participation in the study based
      on the results of eligibility assessment during the run-in period will be randomized to the
      azilsartan 20 mg or amlodipine 5 mg group at a ratio of 1:1 according to the following
      stratification factors; the type of awake-sleep blood pressure variation determined based on
      the data from ABPM at the start of run-in, complication status (chronic kidney diseases
      [CKD], type 2 diabetes), age, and sex.

      Subjects will start treatment with either antihypertensive after examination for the start of
      treatment (Week 0) and visit the study site every 2 weeks, 5 visits in total, until the end
      of treatment (Week 8).

      Subjects will orally take azilsartan 20 mg or amlodipine 5 mg, according to their group
      allocation, once daily before or after breakfast in the morning.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Nocturnal Systolic Blood Pressure Level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change at the end of a treatment period (Week 8) from the beginning point of an observation period
*Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent)
** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nocturnal Diastolic Blood Pressure Level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Mean Systolic Blood Pressure Level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Mean Diastolic Blood Pressure Level</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">957</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Azilsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan</intervention_name>
    <description>Azilsartan 20mg/day</description>
    <arm_group_label>Azilsartan</arm_group_label>
    <other_name>AZILVA Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5mg/day</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <other_name>Amlodin Tablets etc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade I or II essential hypertension

          -  The sitting systolic blood pressure is in term of 140-179 mmHg, or sitting diastolic
             blood pressure is in term of 90-109 mmHg at the both two time points at the beginning
             of the observation period and at the beginning of a treatment period (Week0)

          -  20 years old or older at the time of the informed consent

          -  Able to give written informed consent before participating in the research

          -  Therapeutic category during the observation period: Ambulatory

        Exclusion Criteria:

          -  Secondary hypertension, grade III hypertension (sitting systolic blood pressure
             greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or
             equal to 110 mmHg), malignant hypertension

          -  More than 2 kinds of antihypertensive agents for treatment on the hypertension

          -  History of taking following medicines within 2 weeks before start of the observation
             period.

        When subject with taking any of the following medicine at the time of informed consent is
        included, stop to take the medicine for determined period after the informed consent.

        I. Antihypertensive agents II. Antianginal agents III. Antiarrhythmic agents (except single
        time use of the lidocaine hydrochloride formulation for anesthesia) IV. Digitalis products

          -  Less than 130 mmHg of mean 24-hour systolic blood pressure and less than 80 mmHg of
             mean 24-hour diastolic blood pressure at the start of the observation period.

          -  History of following circulatory-related diseases or symptoms within 24 weeks before
             start of the observation period.

        I. Cardiac disease: Myocardial infarction, coronary artery revascularization II.
        Cerebrovascular-disease: cerebral infarction, cerebral hemorrhage, transient ischemic
        attack III. Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema

          -  History or complication with the following circulatory-related diseases; Valvular
             stenosis, atrial fibrillation, pharmacotherapy-required angina, congestion heart
             failure, or cardiac arrhythmia, or arteriosclerosis obliterans with symptoms of
             intermittent claudication et al

          -  Day / night reversal

          -  History of hypersensitivity or allergy to Azilsartan, Amlodipine, or related drugs

          -  Participant in any other clinical research

          -  Pregnant, possible to being pregnant, or lactating woman

          -  Mal-control of blood pressure during informed consent to taking antihypertensive agent

          -  Any those the investigator or other researchers consider as unsuitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuo Kario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Professor of Division of Cardiovascular Medicine, Jichi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jyuzen General Hospital</name>
      <address>
        <city>Niihama</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Junn Clinic</name>
      <address>
        <city>Tsushima</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seikei-kai New Tokyo Hospital</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanshukai Doi Internal Medicine Clinic</name>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Junshinkai Nakamura Cardiovascular Clinic</name>
      <address>
        <city>Itoshima</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaki Clinic</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osamura Medical Clinic</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoshi General Hospital</name>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zensyukai Hospital</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakushoukai Sano Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiseikai Higashiasahikawa Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koushinkai Shintomi Naika Clinic</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aoki Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houwakai Sapporo Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitani Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinkotoni Family Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoureikan Shinsapporo Seiryou Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomakomai City Hospital</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hukuyo naika clinic</name>
      <address>
        <city>Itoshima</city>
        <state>Hukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asunaro medical Clinic</name>
      <address>
        <city>Kitakyushu</city>
        <state>Hukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keiseikai Gohshi Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keijukai Itabashi Clinic</name>
      <address>
        <city>Koga</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamata medical Clinic</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koyokai Hanamure Hospital</name>
      <address>
        <city>Ichikikushikino</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izumi General Medical Center</name>
      <address>
        <city>Izumi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iroden Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasu Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Himawari-kai Kanagawa Himawari Clinic</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Saiwai Clinic</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakoukai Kawasaki Rinko General Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakuai Clinic</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaneshiro Diabetes Clinic</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamamoto Clinic</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsuruma Kaneshiro Diabetes Clinic</name>
      <address>
        <city>Yamato</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furuie Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minamisawa Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shintoukai Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuyu-kai Kikuchi Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tani Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higashikatsuyama Nakazawa Naika Allergy Internal Medicine</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinden Higashi Clinic</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiwakai Izaki Clinic</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shoninkai Shonin Hospital</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirano Doujinkai Tsuyama Daiichi Hospital</name>
      <address>
        <city>Tsuyama</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taira Hospital</name>
      <address>
        <city>Wake-gun</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenjin Tanaka Internal Medicine Clinic</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enomoto Clinic</name>
      <address>
        <city>Ageo</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazo Minami Clinic</name>
      <address>
        <city>Kazo</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asukurepiosu Enomoto Clinic</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shibuya Clinic</name>
      <address>
        <city>Kumagaya</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genkikai Wakasa Clinic</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JA Shizuoka Kohseiren Enshu Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimoda Medical Center</name>
      <address>
        <city>Shimoda</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIC Utsunomiya Central Clinic</name>
      <address>
        <city>Utsunomiya</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippori Clinic</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eireikai Niwa Family Clinic</name>
      <address>
        <city>Chofu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keiyu Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashikabutocho Nakajima Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taiseikai Seikoudou Clinic</name>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirookai Kanbara Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ono Medical Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sawai Medical Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinsei-kai Kameido Ekimae Ckinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinseikai Kameido Minami-guchi Clinic</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamada Clinic</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitaka Health Care Clinic</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murenosato Clinic</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirayurikai Swing Bldg Nozaki Clinic</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenkoukan Suzuki Clinic</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keichikai Shimokitazawa Tomo Clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishinkai Oda Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryousyukai Kanauchi Medical Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shingakai MaO Clinic</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keiseikai Otsuka Kita-guchi Clinic</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujino Clinic</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirokai Higashikatsura Medical Clinic</name>
      <address>
        <city>Tsuru</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hakataeki-higashi Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogata Medical Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soejima Naika Clinic</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Neurology Clinic</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oda medical Clinic</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiseikai PS Clinic</name>
      <address>
        <city>Hukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosei-kai Nijigaoka Hospital</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seizenkai Okayama Saidaiji Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasuda Clinic</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Nishiumeda Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kouseikai Chimori Medical Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H&amp;Y Akimoto Naika Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiseidou Tomita Hospital</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takahashi Clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <results_first_submitted>November 19, 2015</results_first_submitted>
  <results_first_submitted_qc>November 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2015</results_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was performed at hospital and clinic</recruitment_details>
      <pre_assignment_details>957 patients was enrolled in this study. In run-in period, 239 patients were withdrawn.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azilsartan</title>
          <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="359"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="332"/>
                <participants group_id="P2" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azilsartan</title>
          <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="359"/>
            <count group_id="B2" value="359"/>
            <count group_id="B3" value="718"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="12"/>
                    <measurement group_id="B2" value="61" spread="12"/>
                    <measurement group_id="B3" value="61" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinic SBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149.6" spread="10.2"/>
                    <measurement group_id="B2" value="150.5" spread="10.2"/>
                    <measurement group_id="B3" value="150.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinic DBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.3" spread="9.4"/>
                    <measurement group_id="B2" value="89.8" spread="9.6"/>
                    <measurement group_id="B3" value="90.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour SBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150.6" spread="13.0"/>
                    <measurement group_id="B2" value="152.4" spread="13.7"/>
                    <measurement group_id="B3" value="151.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-hour DBP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.3" spread="8.6"/>
                    <measurement group_id="B2" value="90.4" spread="9.3"/>
                    <measurement group_id="B3" value="89.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Nocturnal Systolic Blood Pressure Level</title>
        <description>Change at the end of a treatment period (Week 8) from the beginning point of an observation period
*Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan</title>
            <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nocturnal Systolic Blood Pressure Level</title>
          <description>Change at the end of a treatment period (Week 8) from the beginning point of an observation period
*Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="15.4"/>
                    <measurement group_id="O2" value="-17.5" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**</title>
        <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent)
** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan</title>
            <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**</title>
          <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent)
** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>riser</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" lower_limit="-10.0" upper_limit="-4.5"/>
                    <measurement group_id="O2" value="-10.1" lower_limit="-13.5" upper_limit="-6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-dipper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.9" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-3.1" upper_limit="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dipper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.6" upper_limit="5.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.3" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>extreme dipper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-3.9" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-4.9" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nocturnal Diastolic Blood Pressure Level</title>
        <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan</title>
            <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nocturnal Diastolic Blood Pressure Level</title>
          <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="8.5"/>
                    <measurement group_id="O2" value="-8.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Mean Systolic Blood Pressure Level</title>
        <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan</title>
            <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Mean Systolic Blood Pressure Level</title>
          <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.0" spread="13.3"/>
                    <measurement group_id="O2" value="-17.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Mean Diastolic Blood Pressure Level</title>
        <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan</title>
            <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Mean Diastolic Blood Pressure Level</title>
          <description>Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="7.5"/>
                    <measurement group_id="O2" value="-8.9" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azilsartan</title>
          <description>Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Azilsartan: Azilsartan 20mg/day</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine</title>
          <description>Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Amlodipine: Amlodipine 5mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nettle rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious disease</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="359"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="359"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PIs is that PIs must get approval about publish by study director(Kazuo Kario).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoyuki Takano</name_or_title>
      <organization>Sogo Rinsho Medefi Co., Ltd</organization>
      <phone>+81-3-6901-6079</phone>
      <email>takano.naoyuki@sogo-medefi.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

